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Abstract 
Brain tumors, such as glioblastoma multiforme, have extraordinarily low five-year 
survival rates. Currently, it is difficult to monitor in real-time the progression of a tumor and how 
it responds to therapy. Biosensors been used to measure key metabolites, such as lactate and 
glutamate, at shorter time intervals to detect abnormal blood levels. In this study, an enzymatic 
coating to detect lactate was developed in vitro.  Chitosan was used to immobilize lactate 
enzyme. The chitosan with the enzyme was coated a glassy carbon electrode and tested at 
different concentrations of aqueous lactic acid as a proof of concept. The results from the 
amperometry indicate that the absolute value of the current output increases when the lactic 
concentration increases. A lactate biosensor utilizing chitosan film has potential for future 
applications diagnosing brain cancers such as glioblasoma by detecting blood lactate levels both 
in vitro and possibly in vivo. 
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Chapter 1: Introduction 
 
Brain cancer and brain diseases affect millions of people and families worldwide. In 
2010, there were an estimated 22,000 new cases of brain and nervous system cancer diagnosed in 
the United States alone (Jemal, 2010). Both males and females in the age range of 15-44 years of 
age have 5-year survival rates of approximately 50-60% (Saikai, 2015). One kind of brain 
cancer, glioblastoma, is especially aggressive and only has a 5-year survival rate fewer than 2% 
(Pirzkall, 2009). No treatment options for glioblastoma are curative; early detection is an area of 
focus for increasing lifespan and quality of life (Tran, 2010).  
Tumors can also develop in the brain as a result of cancer in another part of the body. If a 
patient‘s cancer is determined to be metastatic, it means the cancer has developed enough that 
the cancer cells from a tumor can break off and migrate to the brain through the blood from their 
point of origin (such as the lungs, breast, etc.). This is very common; approximately 20-40% of 
people with cancer will develop metastatic cancer spread to the brain (Serres, 
2012).  Unfortunately, many of these tumors are not diagnosed earlier as they are small and often 
asymptomatic. In most patients the metastatic brain cancer is not diagnosed until the patient 
becomes symptomatic, and the prognosis for the patients is much worse than those where tumors 
were detected early on (Sun-Young, 2005).  
One of the current methods for diagnosing and monitoring brain tumors is by using 
magnetic resonance imaging (MRI). While MRI can be a useful tool to detect these tumors, they 
do have limitations. An MRI does not monitor a patient very frequently, and months can go by 
before a patient has another scan to check for tumors. This is not ideal due to the high mortality 
rate of patients whose tumors were not detected early. A patient may also have a 
physical limitation that limits their ability to be scanned in an MRI machine. Patients that have 
10 
 
pacemakers, heart valve replacements, aneurysm clips, cochlear implants, and those taking 
neuro-stimulators can be unable to be scanned in an MRI due to the way the machine uses 
magnets to create the images (‗Magnetic‘, 2013). MRI results are not always obtained quickly 
due to the fact that test results must pass through many hands for interpretation. After a 
technician has performed the MRI, they then have to pass on the resulting scans to a doctor, and 
then the doctor must read and interpret the results before speaking with the patient. This 
ultimately becomes a time consuming and expensive process. 
An MRI is also expensive; it can cost thousands of dollars, and can be especially 
expensive if contrast is needed or the patient requires drugs due to claustrophobia. It can also be 
time consuming as a scan of the brain can take anywhere from 20-45 minutes or longer if the 
patient moves during the imaging (Meng, 2011). 
Because of the limitations of current imaging systems, there is a need for a way to 
monitor a patient for brain tumors early and often. One way to achieve this is through the 
monitoring of lactate levels in the blood. Increased lactate in the blood can indicate an 
abnormality in cell replication as a byproduct of respiration (Goodwin, 2007). 
The principal goal of this project is to create an effective technique for the early detection 
of tumor growth by the in vitro measuring of lactate, using a noninvasive method. The technique 
in the proposed project can be performed more frequently and efficiently than the current 
standard of screening. This will allow for early tumor detection and an increased chance of 
treatability. Patient limitations such as pacemakers would be avoided. In addition, this project 
could also aid in the diagnosis of other neurological disorders that can cause changes in lactate 
levels due to damage. Testing for lactate levels in the blood could not only be effective for small 
brain tumors but also may be promising for other conditions. 
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One area that shows enormous potential for monitoring metabolite levels is biosensors. 
These are devices where a molecule, such as lactate, binds and initiates an electrochemical 
reaction that becomes an electrical current. The output of current corresponds to the 
concentration of substrate in the initial binding.  Currently, there are many various types of 
biosensors being tested, but their clinical use is limited because of their inaccuracies causing 
electrical interference with the electrical environment in the tissue and/or cells (Fracchiolla, 
2004). Developing a biosensor to work in vitro will allow the enzymatic reaction to be optimized 
for continuous use as an improvement upon current detection methods and as a steppingstone for 
possible future real time monitoring applications in vivo. 
This project is to develop a biosensor capable of detecting lactate for early cancer 
detection. The first step is to determine the different methods in which concentrations of lactate 
can be converted into a measurable electrical signal by the biosensor. The best materials will 
then be selected so there will not be impediment or false enhancement of the signal. Finally, the 
biosensor will be tested with a known static lactate solution as well as several different known 
concentrations consecutively in order to determine the effectiveness of the film in real time 
testing. In order for the design to be considered a success, the biosensor must be capable of 
accurately detecting lactate in an in vitro setting without the sensitivity of the sensor decreasing 
rapidly.  
The following report contains literature review, methodology, data collection, analysis, 
and conclusion sections, to describe in more detail, the process put into designing and testing the 
lactate biosensor, for improved brain tumor diagnostics. 
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Chapter 2: Background and Literature Review 
Brain Cancers 
Tumors in the brain can be extremely hazardous to the health of humans, whether they 
originate in the brain or the result of metastatic cancer from other locations in the body. Tumors 
are divided into two different categories, benign or malignant. If a tumor is categorized as 
benign, this means it is not harmful while a malignant tumor is cancerous and has the potential to 
spread to other parts of the body. Within the category of malignant tumors, there are primary and 
secondary brain tumors. Primary brain tumors originate and proliferate in one site, while 
secondary brain tumors are the result of migrating tumor cells that find a new location to 
proliferate. Glioblastoma is one of the most aggressive types of malignant primary brain tumors. 
The average survival rate for a person with glioblastoma is 5 years and under 2% (Pirzkall, 
2009). Secondary brain tumors are very prevalent in cancer patients, and 20-40% will develop 
them (Serres, 2012). It is also important to note that constant monitoring for these tumors is 
difficult, as well as costly because the current standard of monitoring is MRI.  
Several methods of treatment are currently available for tumors. Chemotherapy is the 
treatment of cancer using drugs, while radiation therapy is uses radiation to treat cancerous 
tumors (Lombardi, 2014). A third tumor treatment method is surgery, which entails physically 
removing the tumor via an invasive procedure. The most commonly used method of tumor 
treatment is combination therapy, which combines the aforementioned treatments used in 
conjunction with one another to attempt to maximize the chances of successful treatment 
(Lombardi, 2014).  
These methods can be invasive and painful, however, earlier detection may catch the 
tumor before significant metastasis, may require less invasive treatment. Early detection also 
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improves the probability of successful treatment and the patient will require less intense 
treatment. 
Lactate Levels 
Because of the limitations of current imaging systems, there is a need for a way to 
monitor a patient for brain tumors early and often. Lactate levels in the blood are measured in 
order to indicate whether or not the body is processing this cellular byproduct correctly, or if 
there is some type of disease within the body causing an excess buildup of this material. Test 
results indicating an excess buildup could be indicative of a number of problems, particularly 
excessive cell growth. Normal lactate levels in the blood of the human body are between 
0.5mmol/L lactic acid and 1mmol/L of blood. When lactate is out of the normal range and rises 
and rises above 2mmol/L (sometimes rising as high as 5mmol/L) this is often indicative of some 
type of disease within the body (Goodwin, 2007). For this reason, it is important to measure 
lactate levels in the blood in order to look for signs of illness. When an increase in lactate levels 
is observed, this often indicates that the body is beginning to undergo anaerobic metabolism, and 
there may be an abnormal and sharp increase in cellular activity. When the body cannot process 
this lactate quick enough or correctly, lactate levels will rise. It is important to note that there is a 
proper and improper time to test for lactate levels in the blood. A proper test time is when the 
body has been at rest and not exerted. Post-exercise or exertion, the body may have higher levels 
of lactic acid in the blood, which may produce an inaccurate test result and a false reading 
(Goodwin, 2007). 
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Current Methods of Cancer Detection 
MRI 
Brain tumors are currently detected by imaging. There are different ways to image the 
brain to check tumor formation, including Magnetic Resonance Imaging (MRI) or Computerized 
Tomography (CT) scans.  
An MRI is the most common method of imaging tumors (Levy, 2014). Patients who have 
been diagnosed with a brain tumor (or are at high risk for a tumor) are scanned to determine the 
extent and location of a tumor(s). This kind of imaging works by utilizing a strong magnetic field 
to align the axes of hydrogen atoms found throughout the body. When the magnetic field is 
removed, different tissues take different amounts of time to realign normally. By measuring the 
difference in these times, an image can be created. This image includes tumors (Berger, 2002). 
The advantage of this kind of imaging is that it is non-invasive, and the risk of complication is 
low, especially if there is no contrast material injected. MRIs are effective for tissue imaging 
because the hydrogen atoms used for the imaging are found in water. Soft tissues contain a lot of 
water and therefore the detail and clarity of the image can detect around 4mm in diameter 
(Yokoi, 1999). While this kind of imaging has many advantages, there are some limitations that 
leave room for improvement. The scans require a patient to come into the hospital or imaging 
center and stay very still for a scan that can take around 20-45 minutes at minimum (Meng, 
2011). When trying to detect small tumors, contrast material, typically delivered by 
nanoparticles, is injected to enhance the difference in the image of the tumor from the 
surrounding tissue (Mortiz, 2003). While this process increases the visibility of tumor cells, it 
does increase the time the scan takes. This process can be time consuming for the patient and the 
doctors as well as relatively expensive.  Before insurance, it is estimated that a scan can cost 
thousands of dollars (Meng, 2011). This cost is due to the size of the machine and the space 
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needed to house it, the length of the procedure, the possible contrasts or dye, and the number of 
people required to take a scan, analyze it, and provide the patient with the results (Meng, 2011). 
In a study of cost analysis for MRI compared to mammography for detecting breast cancer, the 
cost of the MRI ended up being $18,167 over 25 years for the patient, compared to 
mammography which cost $4,760 (Moore, 2009). These scans can be a financial burden on the 
patient as well as on the hospital and physicians. Usually when monitoring a patient for a 
recurring condition, these scans occur about once every six months. This leaves time in between 
scans for tumors to originate and develop. These tumors are then able to grow larger undetected, 
which can increase the probability that the tumor will be more difficult and take longer to treat. 
Sometimes a patient‘s medical condition can also limit their ability to be imaged. An 
MRI utilizes magnets, meaning it can be very dangerous for patients with metal objects 
implanted in them, such as pacemakers (Berger, 2002). The pacemaker could stop functioning 
properly, or a metal implant could shift. These patients are then unable to be monitored for any 
brain tumors or abnormalities using this kind of imaging.  
CT 
A different method of imaging is the CT (computed tomography) scan. During a CT scan 
X-rays are applied from many different angles to create a 2-D image of each section, or slice, of 
the brain. An advantage of a CT scan is that it generally takes less time than an MRI, and this can 
be somewhat helpful for a claustrophobic patient. The images produced by CT scans can be used 
for the imaging of soft tissues as well as bones and blood vessels (‗Mayo Clinic‘, 2015). 
Therefore by looking at soft tissues, differences in the normal makeups that are found can be 
used to locate tumors. However, these scans have a significantly lower resolution than the state 
of the art MRI scans can provide. This means that there is a greater possibility that small tumors 
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can be missed. In Figure 1, a CT scan is shown on the left compared to an MRI scan on the right. 
The CT scan also comes with the additional radiation due to the number of X-rays taken. This is 
not a preferred method of imaging because of this radiation exposure. The average conventional 
x-ray of the head will expose a person to 0.07mSv of radiation, whereas the same CT scan will 
have an exposure of 2.0 mSv (Smelka, 2007).  
 
Figure 1: CT Scan Alongside MRI Scan (“Is MRI”, 2007) 
Imaging Limitations 
While the MRI is the current gold standard in screening for tumors in high-risk patients, 
its limitations leave room for advancement in the way of constant monitoring. While an MRI is 
able to detect a tumor that is only around 4mm in diameter, this is usually only done every 6 
months. Any way to more frequently monitor the patient for any indication of tumor growth 
would be an improvement, and allow scans to confirm a possible diagnosis rather than be the 
only method of detection with such a large time gap in between scans. 
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Biosensors 
Biosensors show great promise for future applications in this area. Biosensors are used in 
many fields including environmental pollutants, food quality, and glucose monitoring (Bãnicã, 
2012). Clearly, biosensors are very versatile and their potential uses are growing. In a very basic 
sense, a biosensor detects levels of a certain molecule, protein, enzyme, element, etc. and 
converts that into an electric current through a reaction on the surface of the biosensor. This 
current is then used to determine concentration of the substance being tested for. Early models of 
biosensors were known as ―enzyme electrodes‖ (Palchetti, 2010).  
This kind of technology already is utilized for the treatment of diabetes. A glucose monitor is a 
biosensor for glucose levels in the bloodstream (Heinemann, 2013). This is an example of 
consistent monitoring by the patient without having to go into the hospital or care center and 
disrupt their life. The monitoring allows the patient to know if there is an abnormal glucose level 
and to either treat themselves or contact their doctor. This kind of constant monitoring is desired 
for monitoring patients at risk for a recurring cancer. 
Medical Applications 
As mentioned before, one of the major current medical applications of biosensors is their 
use in glucose detection, which accounted for roughly 85% of the world‘s biosensor market in 
2004 (Yoo, 2010). Glucose biosensors can be used in vivo and in vitro. Applications of 
biosensors in vivo are somewhat invasive, as they require the sensor to be implanted within the 
body of the patient to detect the glucose. A glucose biosensor in vitro is used on a biological 
sample, in this case blood, to the sensor outside of the body to get a glucose reading (Mandal, 
2010). Glucose biosensors are primarily used for the monitoring and treatment of diabetes 
mellitus, commonly just referred to as diabetes. By using these glucose biosensors, diabetes 
patients can monitor their blood glucose levels, using the in vitro type of sensor, without the need 
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to go to the doctor‘s office for every reading. This allows for the treatments of insulin to be 
tailored to the whether or not high levels of glucose are detected (Yoo, 2010). As glucose levels 
can vary in the blood based on several factors, it is preferable to an alternative taking a constant 
amount of insulin per day. Additionally, it may give the patient and doctor a different perspective 
on the severity of the diabetes (Yoo, 2010). A hypothetical example is that the patient could have 
had abnormal glucose levels show up during a lab test, but when the glucose levels are 
constantly monitored day to day, they usually stay at normal levels or are borderline high. This 
revelation may change the treatments to noninsulin and nutrition therapies rather than constant 
insulin injections (Yoo, 2010). 
Metabolite Biosensor 
Lactate Reaction 
Lactate is from an oxidation-reduction reaction, specifically when lactate is converted to 
pyruvate. Lactate dehydrogenase is the enzyme that catalyzes the reaction. Lactate becomes 
oxidized when it loses two electrons and becomes converted to pyruvate. As this occurs, lactate 
and NAD
+
 bind to lactate dehydrogenase, which creates NADH. The full reaction scheme is 
shown in Figure 2. 
 
Figure 2: Lactate Dehydrogenase Reaction (“Coupled”, n.d.) 
 As this reaction runs in both directions, pyruvate can also produce lactate, and depending 
upon electron strength and currents from the reaction, this will indicate the concentration of 
lactate that must be detected by the biosensor (―Lactate‖, 2016).  
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 Another enzyme that can be used in this film to detect lactate is lactate oxidase. When in 
the presence of lactate and oxygen, the lactate oxidase catalyzes the reaction:  
Lactate + O2 ⇔ Pyruvate + H2O2 
Lactate will still cause the gaining of 2 electrons by the system when it is converted into 
pyruvate, and hydrogen peroxide is also formed (―Enzymatic‖, 1999). A reaction schematic for 
lactate oxidase is shown in Figure 3. 
 
 
Figure 3: Redox Reaction with HRP (Freire, 2003) 
Nanoparticles 
Nanoparticles are materials that are smaller than 100 nm. They have been used in such 
applications as medical imaging, as well as gene therapy and drug delivery (Murthy, 2007). 
Nanoparticles can also be used to enhance the sensitivity of electrochemical biosensors. For 
biosensor applications a class of materials known as noble metals are used due to their 
exceptional properties. Gold and platinum nanoparticles are noble metals that are heavily 
documented in biosensor applications. This is due to their great catalytic properties that can 
facilitate chemical reactions and helping to increase the ability of the nanotubes to transport 
electrons (Kang, 2008).  
20 
 
Enzyme Immobilization 
 In many cases, the enzymes are bound to nanomaterial (nanotubes, nanoparticles). These 
nanoparticles carry the charge (the electrons) to the electrode. There are different methods to 
immobilize the enzymes on the surface of nanoparticles including adsorption, covalent bonding, 
encapsulation, entrapment, and cross-linking (Datta, 2013)(Figure 4). Adsorption is physically 
binding the enzyme to the surface of the nanomaterial. Mixing the enzyme into a solution and 
allowing the nanomaterial to incubate with the solution typically does this. Then the enzyme that 
did not bind is rinsed off. This method is simple, however the bonds that are made between the 
enzyme and the surface are not particularly strong. This is a problem because the biosensor will 
not be stable over time when the enzyme breaks off of the surface; the detecting ability will be 
hindered. The enzymes can break these weak bonds with slight changes in temperature, pH, or 
even mechanical force.  
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Figure 4: Methods of Enzyme Immobilization (Shomu’s Lab, 2015) 
 
 One method used to combat this problem is to adhere the enzymes within a polymer film. 
Electropolymerized films are polymers attached to the electrode with the enzyme in it. One very 
commonly used electropolymerized film is polypyrrole (PPy). The advantages of this film are 
that its electrical conductivity is stable, and it can be synthesized in a neutral environment in 
terms of oxidation potential and pH (Sassolas, 2011). This means that the environment for the 
enzyme is as stable as possible and enzyme denaturing is limited. Another electropolymerized 
film is made out of polyaniline. This film is used because the conductivity of the film can be 
controlled based on how it‘s formed. Polyaniline is a great electron transfer mediator, as well as 
polypyrrole.  
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 Another kind of film used to immobilize the enzymes is polysaccharide films. These 
include materials such as alginate and chitosan. These films are advantageous especially when 
the biosensor has potential for in vivo use because they are non-toxic and biocompatible. These 
films avoid enzyme leakage while allowing substrate to get to the enzyme (Sassolas, 2011). 
Immobilization by crosslinking is when one enzyme is chemically cross-linked to 
another. While this does keep the enzymes on the surface, enzymes are denatured because of 
chemical alteration, thus decreasing the sensing capability of the biosensor. Immobilization by 
covalent bonding can also cause some enzyme denaturing, and the amount of enzyme that is 
fully immobilized on the surface is relatively low compared to other methods (Datta 2013). 
Enzyme immobilization by affinity increases enzyme availability by correcting the orientation of 
all the enzymes. This avoids any blocking or deactivation of the active site of the enzyme. 
However, the correct orientation of the enzymes is achieved by binding a specific group that has 
an affinity to the surface to the enzyme. This can be expensive and time-consuming (Sassolas, 
2011). 
Electrodes and Sensing Technology 
 
The final stage of the biosensor reaction is the electrode. After the lactate reacts with the 
surface of the biosensor, the resulting electrons are sensed by electrodes near the surface of the 
electrode and transduced into a signal. 
Traditional electrodes that are used in electrochemical biosensors are metal electrodes 
(ex. gold, copper, platinum, etc.) and glassy carbon electrodes. However, they tend to suffer from 
issues such as relatively low sensitivity and greater response times (Balasubramanian, 2006).   
Materials in the form of nanotubes are another type of electrode used in electrochemical 
biosensors, either in combination with traditional electrodes, or as a replacement 
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(Balasubramanian, 2006). Carbon nanotubes (CNT) are relatively commonplace and TiO2 is a 
potential competitor, there are other additional materials used for as electrodes in biosensors. 
These less commonly used materials are silver-based and silicone-based (Higson, 2012; Yudin, 
2007). 
The most common materials used are carbon nanotubes, which come in many different 
forms. CNTs are semi-conductors and are therefore useful in the electron transportation utilized 
in electrochemical biosensors (Balasubramanian, 2006). There are two types of CNTs, the 
single-wall carbon nanotubes (SWCNT) and the multi-wall carbon nanotubes (MWCNT). 
SWCNTs are formed from one sheet of graphene, which means that the walls on the nanotube 
are only one atom thick. The MWCNTs are made from separate graphene sheets being layered 
over one another.  
Two of the most common methods of configuring CNTs are CNT-coating electrodes and 
CNT-binder composite electrodes. The CNT-coating electrode transducers are usually covered 
by a Nafion film, which helps prevent fouling of the biosensor, as well as helps to make the 
sensor more biocompatible, on top of the benefits of CNTs. The transducer is what converts the 
detected electrons into a signal detailing the information that has been detected. Additionally, the 
CNTs can be formed in vertically aligned nanotube electrode array, another type of CNT-
coating. In this configuration the CNTs are attached perpendicularly to the underlying electrode. 
CNT-binders are biocomposite electrodes. One type combines paste electrodes with CNT, which 
is a more usual approach to the composite type. A composite electrode can also be made using a 
composite of CNT and Teflon. In the case of the CNT and Teflon composite, the nanotubes are 
used as the transducer, without the need for a secondary electrode (Wang 2004).  
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Titanium (Ti) is a biocompatible material that has many biomedical applications in its 
pure metal, alloy, and TiO2 forms. Titanium has a very high biocompatibility, and is therefore 
very suitable for implantation within the body in orthopedic applications, as well as several 
others. Titanium dioxide, TiO2, is a particularly important form of titanium, with qualities such 
as being a semi-conductor and having a high level of biocompatibility (Li, 2005). TiO2 can be 
used as a film on the surface of other materials to increase the biocompatibility of implants. 
Additionally, nanotubes and nanoparticles made from TiO2 have started to come on to the 
technology scene as an alternative to carbon nanotubes. Multi-walled carbon nanotubes have 
been composited with TiO2, which was shown to increase the photoactivity of the nanotubes 
(Cendrowski, 2014). TiO2 also show stability and little to no degradation when exposed to a 
wide range of pH levels from 2-12, unlike porous silicon which starts to degrade significantly at 
pH‘s exceeding 8 (Mun, 2010). 
Biosensor Limitations 
As mentioned in previous sections, there are two different ways that can be utilized by a 
biosensor to collect information, in vivo and in vitro. Both of these classes of biosensors have 
limitations that may cause them to fail to accurately collect data or not operate correctly.  
In vivo only limitations: 
The first limitation for biosensors implanted inside the body is known as biofouling. 
Biofouling is when proteins, cells, and other objects accumulate on the surface of the biosensor 
and imped its readings. However, there are several ways in which this can be combatted by 
various methods such hydrogel coatings, diamond like carbons, and covalent attachments 
(Wisniewski, 2000).  
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In vivo and in vitro limitations:  
Interference can be a limitation to both in vivo and in vitro biosensor. A physical barrier 
on the biosensor that inhibits the transducer producing a quality signal reception can cause 
interference. ―Road block‖ interference‖ is another name for this phenomenon. It usually occurs 
when the outer layer of the biosensor has hydrophobic properties (Van Antwerp, 1998).  
Interference 
A further interference limitation of biosensors is specific to the enzymatic biosensor 
subset. As stated previously, enzymatic biosensors use the oxidation of peroxide to determine the 
quantity of the substrate present. This is problematic because the biosensor requires a relatively 
high current input to oxidize the hydrogen peroxide. This current can have a side effect of also 
oxidizing other electroactive substances that may be contained in biological samples, such as 
ascorbate and urate. This would cause the measurement reading to be higher than the true 
substance level (Rad, 2012). Additionally, there are relatively significant levels of hydrogen 
peroxide in human tissue that also has a potential to be oxidized by the biosensor (Halliwell, 
2000). In summary, not all of the peroxide oxidized by the biosensor is the result of the targeted 
substance for measurement, causing a need for an established baseline. 
Patents 
In addition to the published findings that researchers have discovered with respect to how 
biosensors and the materials that make the up work, a great many patents have also been filed. 
The following two patents are examples of different ways that have been used to develop a 
biosensor that can detect glutamate. 
A patent was filed in 2003, and issued in 2008 in the United States for a nanobiosensor 
that utilized carbon nanotubes. The patent for this biosensor, US Patent No 7399400 B2 details 
that this biosensor was originally designed to sense glucose. However, in the claims section of 
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the patent, it states that the biosensor could be modified to use glutamate oxidase instead of 
glucose oxidase in its redox reaction, which should allow the biosensor to detect glutamate. The 
patent also states that the usage of the carbon nanotubes as part of the biosensor caused the 
biosensor to have an enhanced sensitivity (Soundarrajan, 2008). 
Another patent discovered was for a biosensor that is meant to detect glutamate in food, 
sometimes known as MSG. This patent WO Patent No 2007114650 A1 was filed and issued in 
2007 with the World Organization. This biosensor was designed to utilize nanowires made from 
either silicone or zinc oxide to detect the electrons given off from an enzymatic reaction without 
using additional nanoparticles (Hong, 2007). 
One lactate biosensor patent was also discovered, where the design was to detect levels of 
lactate in whole blood. This design utilized a layer-by-layer technique with 
carboxymethylcellulose (CMC), carbon nanotubes and lactate oxidase. These components were 
used successfully in a disposable biosensor for lactate in blood. This design improved upon a 
carbon electrode, which the authors acknowledged does have poor surface redox properties when 
compared to other electrodes. Utilizing the carbon nanotubes helped to amplify the signal from 
the reaction (―Biosensor‖, 2003). 
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Chapter 3: Project Strategy  
 
Overall Client Statement 
For this project it is important to cater to the needs and desires of the client, while making 
sure the design solves the problem at hand and is possible in the time or budgetary constraints. 
At the beginning of this project, the client statement was very broad. This client statement 
was: ―Develop a practical biosensor enzyme coating to measure levels of extracellular glutamate 
consistently and accurately‖. While this gives a basic idea of the project, a more specific 
statement was developed after further research and discussion with the client. 
From discussions with the client the important and novel component of the biosensor was 
specified to be the titanium dioxide electrode that would be used. Titanium dioxide is 
advantageous because of its great electron transport and sensitivity (Cendrowski, 2014).  The 
project was also specified so that the biosensor would be designed to be used in vitro. This 
means non-invasive procedures for the patient with potential for future real-time monitoring of 
metabolite levels. It was also specified that metal nanoparticles would be used to further increase 
the sensitivity of the biosensor. These nanoparticles can be bound to the inside of the 
nanotubes.    
In the next meeting with the client, the project was split between this group and a MQP 
group from the Chemical Engineering department. This led to the responsibility for the titanium 
dioxide nanotubes to be given to the Chemical Engineering group. Therefore, the focus of this 
project narrowed to characterizing and optimizing the enzymatic reaction. So, this led to an 
updated client statement: ―Characterize, develop, and optimize an enzymatic reaction on 
nanoparticles for a glutamate and/or lactate biosensor. The biosensor will utilize titanium dioxide 
nanotubes and detecting levels of glutamate and/or lactate in vitro”. Detecting lactate was added 
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to the client statement because the Chemical Engineering group was originally going to develop 
a biosensor for lactate. After further research and discussing the options with the client, lactate 
was selected as the project‘s focus due to project limitations such as timeline and funds, leading 
to the final client statement: ―Characterize, develop and optimize and enzymatic film for a lactate 
biosensor. The biosensor will utilize titanium dioxide nanotubes and detect levels of lactate in 
vitro‖.  
Objectives 
 
Primary Objectives 
The primary objectives of the project are to make sure the biosensor: (1) can detect 
lactate, (2) is reliable, (3) is user friendly, (4) is adaptable, and (5) is non invasive. These 
objectives can be seen in Figure 5. 
 
Figure 5: Objective Tree 
Detect Lactate: It is important for the purposes of this project for the sensor to detect lactate. 
The different sources that lactate will be detected from are known and unknown lactate solutions, 
and from in vitro cell cultures. This will be the same for lactate. However, future applications of 
this kind of biosensor may be in vivo, and therefore invasiveness and biocompatibility are 
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significant concerns. Methods and designs for this project should be done in consideration of 
this.  Using the biosensor in vitro is ideal because it is non-invasive and this can warn the patient 
of any lactate system irregularities in their brain. 
Reliability of lactate detection: Our next objective is to validate the reliability of the biosensor. 
This biosensor should detect any amount of lactate in the blood. For detecting lactate the sensor 
should be able to distinguish between mmol/L levels of lactate, as anything above 2mmol/L is 
considered abnormal (Goodwin, 2007). 
User Friendly: The next objective of this project is to make sure the biosensor is user friendly. 
The reason for making the biosensor user friendly is so the product can be distributed without 
any required specific training. This will save money and resources in potential clinical 
applications if no staff has to take time to become familiar with the sensor. User-friendliness is 
also important if future use is by the patient. They will have to safely and properly use the sensor 
based on a set of written instructions and any suggestions of their physician. 
Non invasive: The biosensor is used to help diagnosis illness within people, so it is important 
that it is not invasive, which may lead to complications that actually cause a problem when the 
purpose of the procedure was to prevent a problem. 
Adaptability: The final objective in the project is to make sure the enzymatic reaction is 
reproducible and relatively simple as well efficient and stable. The reason for this is so that other 
molecules that indicate brain disease or cancer, such as glutamate, can be sensed with similar 
accuracy. The ranked objectives can be seen in Figure 6. 
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Ranking the Primary Objectives 
 
 
Figure 6: Primary Objective Ranking Chart 
The rankings for the objectives are based on what was deemed to be the most important. 
A table of objectives ranked 1-4 is shown in Figure 7. The most important part of this project is 
the detection of lactate, which is why it is the top ranked objective. Reliability was the objective 
that was determined to be second most important. The sensor should not miss any lactate in the 
solution, cells, or blood that it is tested with. It is equally important that false reading is never 
given; the biosensor should be very reliable. The third ranked objective was that the device be 
non-invasive. By being non-invasive, the device will not cause adverse effects in the patient, 
such as inflammation. Ranked fourth out of five was that the biosensor be potentially adaptable. 
This is important if any changes need to be made throughout the project or if the sensor has 
potential for use with different substrate in the future. The final objective is user friendliness. 
This biosensor should not require any significant amounts of training beyond what a qualified 
person should already have. In the future this could be expanded to patients.  
 
Figure 7: Objective Ranking 
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Secondary Objectives 
The following are the secondary objectives of the project. The secondary objectives are 
objectives that are consist of what needs to be realized to achieve the primary objectives of the 
project. 
Optimize enzyme reaction: The enzyme reaction is critical to the detection of the lactate, as the 
reaction is what breaks the enzyme down a form that can be detected (electrons). 
Synthesize TiO2 nanotubes: The TiO2 nanotubes will act as an electrode, outputting a signal 
based on the quantity of electrons, or current level, produced by the enzymatic reaction. These 
nanotubes will by synthesized by the work of the Chemical Engineering team. 
Accurate: the biosensor must read the correct level of the lactate within a small percent error in 
order to be useful. 
Prevent Degradation: The materials (enzymes, nanoparticles, nanotubes, etc.) that make up the 
biosensor must retain their properties for a minimum period of time. The biosensor must be 
capable of working properly for that minimum time period to be considered useful. 
Manufacturers of glutamate and lactate biosensors typically guarantee the biosensor to last and 
perform optimally for 21 days after the shipment of the sensor is received (Pinnacle 
Technology). Taking this into account, as well as the known degradation rates of the chemicals 
on the sensor, the longevity of our biosensor should be roughly 25 days. After 25 days, these 
types of biosensors are not guaranteed to perform correctly and may not necessarily detect trace 
amounts of glutamate or lactate. However, once the sensor has been used, it will typically only 
last an additional 5 days while maintaining the expected reading parameters.  
Compatibility: For the purposes of this project, this biosensor must be capable of sensing lactate 
and be able to have its design modified for glutamate. Therefore the enzymatic reactions to 
detect both glutamate and lactate must both be similar. For example, the reaction of glutamate or 
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lactate with their respective oxidase enzymes would both need to produce the same amount of 
hydrogen peroxide per molecule of glutamate or lactate reacted. Otherwise the biosensor readout 
would have to be recalibrated for what each current level meant if lactate and glutamate 
produced different amounts of peroxide per molecule reacted. 
Ranking of Secondary Objectives 
 
Through discussions with the client, the secondary objectives were ranked as follows in Figure 8: 
 
 
Figure 8: Secondary Objective Ranking Chart 
There was a 2-way tie for most important secondary objective. We ranked these 
objectives for many reasons. First we have optimizing enzyme reaction and the reason is because 
the enzyme reaction is critical to the detection of the lactate, as the reaction is what breaks the 
enzyme down a form that can be detected. Also tied for first is synthesizing TiO2 nanotubes and 
the reason for this is it will act as an electrode, outputting a signal based on the quantity of 
electrons, or current level, produced by the enzymatic reaction. We also want it to be accurate so 
this came in as our third objective.  Ranked second to last is "prevent degrading". The last 
objective with a very low score was compatibility. We did not think this was as critical to our 
biosensor. The rankings are shown in Figure 9. 
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Figure 9: Secondary Objective Ranking 
Project Constraints 
In order for a successful completion of the project, it must stay within several constraints 
as defined by the project team and the client. 
 
Budget: The team is limited to a budget of $450. 
Time: The entire project including optimizing the enzyme reaction, data collection, analysis, and 
completion of the written report must be complete by the end of the 2015-2016 academic year. A 
separate MQP project will focus on developing the titanium dioxide nanotubes concurrently with 
the nanoparticle enzyme optimization accomplished in this project. Proof of concept testing 
cannot occur until both the nanotubes and nanoparticles are complete. 
Sensitivity level: The main purpose of this project is to optimizing an enzyme reaction that will 
be able to detect lactate for differences between mmol/L levels. 
Ability to use: The device must be within the capabilities of the members of this project team to 
operate and analyze.  
Equipment: As a result of time and budget constraints the MQP team is limited to the types and 
models of equipment found in Professors Jain and Zhou‘s labs for construction and data testing. 
There was also a limitation with the availability of the AUTOLAB technology in Professor 
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Zhou‘s lab, as our team required someone with access to let us on the system as well as be there 
to monitor testing.  
Project Approach 
The purpose of this project was to develop an in vitro method of detecting metabolites 
produced by a growing brain tumor. This was further narrowed down to the utilization of an 
enzymatic coating with a biosensor to achieve this purpose. Several steps were taken to achieve 
this goal: research, design, testing, data analysis and design improvement, future direction, and 
compilation. This project had a time limit of approximately 28 weeks in which to accomplish 
these steps. 
Research 
It was important to gain as much knowledge as possible after establishing the goal of the 
project. There were three major topics of research required to gain a sufficient understanding of 
the need and requirements. The first topic was brain cancer, with a focus on glioblastoma. It was 
important to understand the prognosis of those affected by these tumors, how the tumors are 
currently detected, and the current treatment options. The second topic of research was on 
enzymatic coatings. This research looked into different enzymes capable of reacting with 
metabolites produced by brain cancer and different materials capable of immobilizing the 
enzyme to a biosensor surface without impeding function. The third topic of research was on 
biosensors. The biosensor research included determining their potential uses, the different types, 
and methods of testing the functionality of a biosensor, including expected data outputs from 
these tests. 
Design 
The next step was the design process. The initial client statement was modified for the 
first time, based on the increased knowledge gained by the research contained within the 
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literature review. By interviewing with the clients, Dr. Jain and Dr. Zhou, the objectives, 
constraints, requirements, and functions of the project were sharply defined. This allowed the 
development of a final client statement, from which the next part of the design process began. 
The next part of the design process was developing several design options for the 
development of an enzymatic biosensor. This focus was mostly on the materials to use in the 
immobilization of the enzyme. Due to the limited budget size and time, it was imperative to 
compare the positive and negative attributes of each design thoroughly prior to building a 
prototype. A final design would be selected, following consultation with the advisors, by 
December 17, 2015. 
Development of Prototype 
The building of the prototype of the chosen biosensor design and utilizing different 
testing methods for validation were conducted concurrently starting on January 14, 2016. The 
purpose for approaching the project in this way was due to the materials involved. As an 
example, it was important to perform material properties testing on the enzymatic 
immobilization material, to determine if it was prepared properly. This concurrent testing was 
important to the later step of validating the design, as it provided a system of checks aimed at 
preventing data becoming tainted by experimental error. The prototype development was 
concluded by March 14, 2015. 
Testing 
Following the successful building of the prototype of the selected design, more testing 
was performed to determine its functionality. The first set of testing was a contact angle analysis, 
as previously stated, to determine if the developed enzymatic coating formed properly. Secondly, 
an assay was performed, modified to compare the mixture of enzyme and immobilization 
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material with the pure enzyme. This would determine if the enzyme could remain active within 
the biosensor coating. 
The next tests were electrochemically based. The first of the electrochemical tests, cyclic 
voltammetry, would determine if and where there was an optimal voltage at which the biosensor 
detected the desired substrate. The second test, amperometry, determined the sensitivity of the 
biosensor to different concentrations of the desired substrate. This was important, as the final 
client statement specified being able to detect levels of lactate, not just whether or not lactate was 
present. The final electrochemical test was a real time amperometry test, where the level of 
lactate was increased at set intervals throughout the test. This was to determine if the data 
outputs for detected lactate concentrations were set only by the enzymatic reactions occurring at 
the beginning of the test or if the biosensor was capable of changing its readout accordingly with 
increased lactate concentration, within the same test. 
Data Analysis and Design Improvement 
The data produced by each type of test was compared to the expected values and trends 
found during the literature review. It was expected that any test had the potential for outliers. 
Therefore, due to the limited duration of the project, the most emphasis was placed upon data 
that significantly contested the theoretical results. Possible causes for the unexpected results 
were researched in literature. Following this the prototype was rebuilt and subjected to a second 
round of the same tests. The new data from each test was then compared to the previous data and 
literature to determine if there was improvement. This cycle continued until any fixable issues 
were resolved with the design and construction of the prototype. 
Future Works 
As previously mentioned, limited time and budget were highly significant factors in the 
process of completing this project. Therefore the final step was to use the implications of the 
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analyzed data, along with published literature, to determine possible directions that this 
technology could take in future work. This is significant as it further solidifies the conclusions 
formed from the analyzed data and provides a platform for the beginning of a new project to 
work off of, rather than starting from scratch. 
Compilation 
All of the previous steps were to be completed by April 18, 2016. They were compiled 
into a final project report over the entire course of the project. This project report was submitted 
on April 28, 2016. 
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Chapter 4: Methods and Alternative Designs 
Materials 
A simple polypyrrole layer serves the purpose of being a conducting polymer. 
Advantages of this material as a conducting polymer include its biocompatibility and that it is 
thermally and environmentally stable. One significant advantage of polypyrrole on its own as a 
conducting polymer is its ability to directly receive and transduce signals from the enzymes of 
the substrate (Ramanavičius et al., 2005). In addition, polypyrrole is known for its ability to 
reduce interference from sources outside of the biosensor film (Ramanavičius et al., 2005). The 
ability of polypyrrole to form nanoparticles is also advantageous in some biosensor applications. 
The major limitations associated with polypyrrole as a biosensor material are its physical 
properties, which can make it difficult to work with in the creation of a biosensor layer. For 
example, polypyrrole has poor ductility, oftentimes making it difficult to process and implement 
into the system (Chen, 1995).  
Another film option for this biosensor is chitosan. Chitosan functions to entrap enzymes, 
allowing for less interference and allows for the achievement of a better and more accurate 
reading. With polypyrrole, this will work well with a conducting polymer because the enzymes 
will be obtained with little interference, and the polypyrrole will be able to conduct a signal for 
interpretation of the sample results. The most notable advantage of using chitosan and 
polypyrrole together in a biosensor is the increased sensitivity and accuracy, making for 
reproducible and accurate results (Senel, 2015). Together, these materials will also create a 
porous surface, mostly attributed to the chitosan, and this is good for trapping test enzymes. 
Limitations of a polypyrrole layer with chitosan include the potentially poor physical properties 
of polypyrrole, especially in acidic solutions. In fact, chitosan layers have been found to break 
down in acidic environments over short periods of time (Islam, 2012). While this break down 
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may be problematic for this material, modifications to chitosan (such as an polymer coating) can 
be made to decrease the rate of the degradation in an acidic environment (Islam, 2012).  
Our biosensor will be detecting levels of lactate. Lactate oxidase (or lactate 
dehydrogenase) will be in the biosensor film to aid or enhance detection by the electrode of 
charge proportional to the level of substrate. Adding HRP may help to amplify this reaction, and 
will be determined through testing whether or not it is an effective addition to the sensor design 
(Senel, 2010).  
Crosslinking, as mentioned in Chapter 2, is a method of enzyme immobilization. There 
are two common materials used in the immobilization process, Poly(ethylene glycol) diglycidyl 
ether, also known as PEGDE, and glutaraldehyde. Crosslinking using PEGDE is less harsh on 
the enzymes than the glutaraldehyde fixation. Therefore the sensitivity of the enzymatic 
biosensors utilizing PEGDE for glutamate detection is more sensitive than biosensors that use 
glutaraldehyde (Vasylieva, 2011). 
The cost of the materials in film designs is in Appendix C. 
Alternative Designs 
The first design chosen was a layer of polypyrrole mixed with lactate oxidase (or lactate 
dehydrogenase) as shown in Figure 10. This was chosen as is the simplest type of polymer-
enzyme coating to develop as the lactate oxidase is simply mixed with the. The polypyrrole-
enzyme is deposited on top of the TiO2 nanotubes electrode using electrophoresis (see Appendix 
A for protocol). Through further research, the layer-by-layer method of coating was determined 
to be a superior method. 
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Figure 10: Single Polypyrrole Layer Design 
In order to incorporate beneficial properties of different materials into our design, layer-
by-layer coating was considered. This coating design would have different materials layered on 
top of another. In a layer-by-layer coating method, each component of the coating is applied as 
its own layer to the surface of the biosensor. The main force behind the layer-by-layer method of 
coating biosensors is the electrostatic force. Electrostatic force utilizes oppositely charged layers 
of polymer films, alternating from positive to negative in each layer. The opposite charges do not 
have to be equal for layer-by-layer coating to be effective (Zhao, 2006). 
One example of a layer-by-layer coating is on a glucose biosensor utilizing a gold 
electrode. The enzyme used in this biosensor, glucose oxidase, is a polyanion, meaning that it 
has a negative charge. The Ferrocene poly(allylamine) (FcPAA) is a polycation, which serves as 
the positive layer. The surface of gold electrode is coated with a monolayer of mercaptan to give 
the surface a negative charge, which is attractive to the FcPAA. It was not stated why the 
mercaptan was used instead of the negatively charged enzyme for the first layer. The ferrocene 
component of the polycation layer is additionally important, as it is known to be a catalyst for 
redox reactions. This is the type of reaction that provides the sensor with a reading (Harper, 
2010). This article mentioned that the major advantage of using the layer-by-layer is to 
immobilize the glucose oxidase to the electrode of the biosensor without inhibiting it. The three 
dimensional structure of the glucose oxidase is unchanged and its overall activity level (rate of 
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glucose catalyzed) is only slightly reduced, as opposed to other more damaging methods 
(Harper, 2006). An interesting take on another layer-by-layer biosensor was made using 
polypyrrole and single-walled carbon nanotubes. The nanotubes and polypyrrole are the layers 
on a platinum-coated polyvinylidene fluoride (PVDF) membrane. Both the nanotubes and the 
polypyrrole (PPy) layers were coated to the biosensor while dissolved in different solutions. This 
biosensor was prepared in two-layer (nanotubes-PPy), three layer (PPy-nanotubes-PPy), and 
four-layer (PPy-nanotubes-PPy-nanotubes) formations, after which each was soaked in a glucose 
oxidase solution to adsorb the glucose oxidase to the surface. The major advantages of the layer-
by-layer method are that it allows the positive qualities of both the nanotubes and the PPy to 
enhance the biosensor because of the specific formation. The environment and thermal stability 
of PPy and the electrical conductivity and chemical stability of the carbon nanotubes may not 
properly contribute if they are applied in the wrong way (Shirsat, 2007). 
To apply these advantages to a film design for our biosensor, layering chitosan and 
polypyrrole was considered. The next design considered was adding a film of chitosan to the 
polypyrrole film mixed with lactate enzyme (oxidase or dehydrogenase). In the initial stages of 
gathering information for the layer-by-layer technique, chitosan was considered as a potential 
polymer to be used in conjunction with the polypyrrole in a layer-by-layer setup shown in Figure 
11.  
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Figure 11: Polypyrrole and Chitosan Layer-by-Layer Design 
The intent was for the chitosan to reduce possible interference. However, through further 
research, it was determined that both the polypyrrole and the chitosan are positively charged. In 
order for the layer-by-layer technique to work properly, a polycation (positively charged) and 
polyanion (negatively charged) for electrostatic forces to apply. Therefore, if the layer-by-layer 
procedure were performed with two positively charged materials, such as polypyrrole and 
chitosan, no electrostatic binding would occur between the layers. Subsequently, it is likely the 
layers will separate. 
Because the layer-by-layer design with chitosan and polypyrrole was not feasible as 
described above, the next inclination was to design a film using a polypyrrole and chitosan 
composite material. This is shown in purple in Figure 12. Through further research, it was found 
that a composite of these two materials would be difficult to fabricate and optimize for our 
design in the time restraint we have (Huang, 2013). Making the composite would result in a 
hydrogel with exceptional water absorbency, but for our applications this composite is not ideal 
or practical (Huang, 2013). 
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Figure 12: Polypyrrole and Chitosan Composite Design 
The next film designs are each variations on one another. These designs are chosen as the 
―ideal‖ designs because they all utilize cross-linking the enzyme (lactate oxidase or lactate 
dehydrogenase) to increase the time before the enzymes are desorbed, and therefore increasing 
the life of the biosensor. PEGDE was chosen as the crosslinking agent because it is less 
denaturing to the enzyme as commonly used glutaraldehyde. This denaturing can cause an 
enzyme to become unspecific, and bind to similar reactants besides the target reactant. One study 
compared PEGDE to other enzyme entrapment materials in enzyme specificity. The results are 
shown in Figure 13. 
 
Figure 13: Enzyme Specificity Comparison (Vasylieva, 2011) 
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 The higher the selectivity constant represents the impact of the immobilization technique 
on the selectivity of the enzyme. PEGDE has less impact on the selectivity of enzyme than 
glutaraldehyde.  
These designs also utilize the properties of polypyrrole and chitosan. These design 
alternatives will all be tested to determine which film is optimal for the biosensor.  
The selected device design shown in Figure 14 is a variation on the traditional layer-by-
layer technique. The first layer is the polycation, polypyrrole, which is deposited onto the 
nanotube surface using electrophoresis (See Appendix A). Then the next layer, a polyanion 
lactate enzyme cross-linked with poly(ethylene glycol) diglycidyl ether (PEGDE) is deposited on 
top of the polypyrrole layer (Appendix A). 
 
Figure 14: Single Polypyrrole Film and PEGDE Crosslink Design 
The design in Figure 15 is an addition on the design of Figure 4. This design would have 
another layer of polypyrrole deposited on top of the PEGDE cross-linked lactate enzyme. 
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Figure 15: Double Polypyrrole Film and PEGDE Crosslink Design 
The design in Figure 16 is a variation on the traditional layer-by-layer, similar to Figure 
14 except chitosan is the polycation layer, in place of the polypyrrole. The chitosan is the first 
layer deposited on the surface of the TiO2 (see Appendix A). Then the polyanion PEGDE cross-
linked lactate enzyme will be deposited on top of the chitosan layer. 
 
Figure 16: Single Chitosan and PEGDE Crosslink Design 
The design in Figure 17 is an addition on the design of Figure 16. This design would have 
another layer of polypyrrole deposited on top of the PEGDE cross-linked lactate enzyme. 
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Figure 17: Double Chitosan and PEGDE Crosslink Design 
Final Film Design 
Our final film design was chosen to be lactate enzyme mixed within a chitosan film 
applied to the titanium dioxide electrode (Figure 18). Chitosan was a chosen material due to its 
ability to prevent interference from cells (for application beyond simple testing in substrate 
solution) and to prevent enzyme leakage (Senel, 2015). The data shown in Figure 13 also shows 
that polypyrrole significantly reduces the specificity of the enzyme, and chitosan has potential to 
perform better than this because it is a natural polysaccharide. This coating method is simple 
enough to synthesize many films to test in the amount of time we are allotted to complete this 
project, and materials needed are already mostly available in the lab, which allows us to reduce 
our spending. This kind of film will allow us to characterize chitosan as a material for this 
application, and evaluate its effectiveness with this kind of electrode. We also chose this design 
because it is easily adaptable to incorporating glutamate oxidase for detection of glutamate in 
future films and tests.  
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Figure 18: Single Chitosan Layer Design 
Due to the fact that the titanium dioxide electrode was not available to coat in time to test, 
the films were applied to a glassy carbon electrode.  
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Chapter 5: Design Verification Results 
Contact Angle 
The chitosan mixture was tested by contact angle analysis. 30µL of the chitosan solution 
was deposited on a glass slide three times. It was important to perform the test in triplicate for 
statistical significance. The measured contact angles were compared to a chitosan film of a 
similar concentration in literature. The chitosan was also inspected for its consistency, to insure 
that it had the viscous behavior detailed in the literature. A photo (Figure 19) was taken of the 
water droplet within 20 seconds of its placement on the dried chitosan film. It sometimes took 
this long due to the difficulty of making the camera focus on the water droplet, which was very 
small. 
 
Figure 19: Chitosan Contact Angle 
The three contact angle measurements calculated with Image J were 72˚, 76˚, and 55˚. 
Cyclic Voltammetry 
The cyclic voltammetry tests changed somewhat over the course of the project. It was 
important to make sure that the voltage span included the potential where the electrode is most 
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sensitive to detecting the enzymatic reaction. The final voltage range to be settled on for testing 
was the same the as the group developing the TiO2 nanotube, -0.4V to 0.8V, however because 
the titanium dioxide electrode was not readily available for testing, all electrode testing was done 
on a glassy carbon electrode. The scan rate was 0.1 V/s. Film that contained lactate oxidase and 
film that contained lactate dehydrogenase were both tested. The results for the lactate oxidase are 
shown in Figure 20 and the results for the lactate dehydrogenase are shown in Figure 21.  
 
Figure 20: Lactate Oxidase Cyclic Voltammetry 
At approximately the -0.2V mark there is a prominent peak in the current for the lactate 
oxidase coating, indicating a peroxide reaction. For the lactate dehydrogenase, there was a 
temporary plateau at the -0.2V mark, but no significant peak formed as in the lactate oxidase. 
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Figure 21: Lactate Dehydrogenase Cyclic Voltammetry 
Amperometry 
The next tests performed were amperometry at different concentrations of lactic acid in 
solution: 0, 100µM, 500µM, 5mM. The amperometry tests were conducted for 120 seconds on 
each concentration. The order of testing proceeded from the lowest concentration, the deionized 
water, to the highest concentration, a 5mM solution of lactic acid. The electrode was rinsed with 
deionized water between each test. Great care was taken with the rinsing to protect the coating 
from removal. These tests were also done with both lactate dehydrogenase (Figure 22) and 
lactate oxidase (Figure 23). 
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Figure 22: Lactate Dehydrogenase Amperometry 
 
Figure 23: Lactate Oxidase Amperometry 
The constant current was set to -0.2V based on the peak or plateau that formed at this 
potential in both enzymatic coating. As the concentration increases for both the lactate oxidase 
and dehydrogenase, the general trend of the absolute value of the current also decreases. 
However, in the lactate dehydrogenase tests, the 100µM concentration was an outlier, showing 
lower current than the deionized water. Additionally, in the lactate oxidase testing, the 100µM 
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concentration was also an outlier as it outputted a higher current than the 500µM concentration, 
and was only slightly lower than the 5mM concentration coating. 
Real Time Testing 
The real time testing of the electrode was performed using an amperometry test. This test 
used the same settings as the concentration testing amperometry. The test began with the 
electrode submersed in deionized water. At the 30 second mark 50µL of a 9.4M lactic acid 
solution were added to the deionized water. It was important to attempt to not touch the electrode 
setup with the micropipette, to prevent changes to the current flow not caused by increased lactic 
acid concentration. A second 50µL volume of 9.4M lactic acid solution was added to the testing 
solution at the 70 second mark. The lactate dehydrogenase (Figure 24) showed a small dip when 
the first amount of lactic acid was added. Following the second lactic acid addition, the current 
significantly increased and remained stable.  
 
Figure 24: Lactate Dehydrogenase Real Time Test 
The lactate oxidase (Figure 25) coating showed several spikes of increased current output 
after the first quantity of 9.4M lactic acid was added, along with a single current spike after the 
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second amount of lactic acid was added. However, unlike the lactate dehydrogenase coating, the 
current did not stay increased, but leveled out higher than the initial deionized water baseline. 
 
Figure 25: Lactate Oxidase Real Time Test 
Colorimetric Lactate Assay Kit Testing of Chitosan Film 
In order to test the viability of the enzyme in the chitosan film, an assay was developed to 
test for enzyme functionality using the lactate assay kit purchased through Abcam. While a 
detailed protocol for this assay can be found in Appendix B, chitosan film was made and put into 
wells in 20ul volumes. Three wells contained chitosan without enzyme, and three wells 
contained chitosan with enzyme. The films were allowed to dry in the fridge for a few days to 
preserve the enzyme, and then the films were blocked with BSA and incubated in lactate at a 
6nmol/well concentration. The hope is that the BSA would block most of the potential lactate 
binding sites in the chitosan and the lactate could bind to the enzyme when incubating after the 
block. The assay was read on a plate reader at 450nm, and the absorbance values for the 
standards in this assay are shown in Figure 26. The standard bar graph shows a linear trend, 
which indicates the assay was run properly. 
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Figure 26: Standard Curve Absorbance 
Figure 27 shows the absorbance values of both kinds of chitosan wells compared to other 
wells that aid in the understanding of the results. Standard 1 is a control with only buffer and 
reaction mix, showing that the chitosan films did at least contain some lactate above this level. 
The background control also provides a similar analysis. Standard 4 has lactate at the same 
concentration as what was put in the chitosan wells. This shows that the levels of lactate left in 
the wells after the incubation period was poor. Finally, there isn‘t a significant difference in this 
assay between the lactate levels in the chitosan without and with enzyme.  
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Figure 27: Chitosan Wells Compared to Relevant Wells 
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Chapter 6: Discussion 
Validity Testing 
There were multiple steps in coating development process that were tested for validity 
prior to testing with the Autolab machine. The initial step was to cross-reference the different 
possible biomaterial coatings with their enzyme and electrode compatibility, as detailed in 
Chapter 3. This was important because, as detailed in the budget section, the limited funds meant 
that there was little room for error by purchasing a material that would have absolutely no chance 
of working. 
The first in lab validity testing was to test the contact angle of the chitosan solution. The 
results of the contact angle measurements showed that the dry chitosan was relatively 
hydrophobic. To improve the accuracy of this test, the literature that was used for the comparison 
also contained data on how the contact angle measurement of the the chitosan film changes over 
time after the water droplet (~10µL) was deposited. This was useful because there was difficulty 
in getting the camera to focus on an area as small as the each of the water drops. Therefore 10 to 
20 seconds may have passed between deposition and capturing the image (Farris, 2011). 
The second test was to perform a lactate assay, modifying the procedure to compare the 
mixture of 15:20 ratio of lactate dehydrogenase to chitosan solution with different standards. 
While the chitosan samples did have a stronger absorbance than the background wells, there was 
no significant difference between the chitosan wells with enzyme and those without. This 
indicates that the lactate may have been blocked from binding well with the chitosan, but did not 
bind well with the enzyme. The procedure for this assay was not the standard use of the kit, and 
variations or changes to the protocol could be made to address this problem. The same test was 
attempted with the lactate oxidase kit that was already in the lab from a previous MQP group. 
Unfortunately, the kit did not produce a measureable reaction, either with the oxidase and 
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chitosan mixture or the standards. This may have been caused by either age or other unknown 
factors. 
The most important tests were performed using the Autolab machine in Professor Zhou‘s 
lab with GPES software. There were two main tests performed: cyclic voltammetry and 
amperometry. For both test the reference electrode made of AgCl and the counter electrode was a 
platinum coil, and the working electrode was the glassy carbon electrode. Both tests were 
conducted initially in deionized water, followed by increasing concentrations of lactic acid: 
100µ, 500µM, and 5mM. For the sets of testing where both cyclic and amperometry readings 
were performed, the cyclic voltammetry was performed first followed immediately by the 
amperometry for each concentration. This was important so that the coating would not become 
saturate with higher lactic acid concentrations. If this happened, and then the electrode was tested 
in a lower concentration, it would be difficult to get an accurate reading due to the concentration 
gradient being flipped for the lactic acid solution. The solution the electrode is tested with should 
have higher levels of lactic acid than the coating. 
The cyclic voltammetry testing was to determine if there was reaction occurring on the 
coated electrode in lactic acid when compared to immersion in deionized water. The voltage 
range of -0.4V to 0.8V was selected as the best testing range. This was decided so that the results 
on the glassy carbon electrode could be compared to the tests on the nanotubes. A peak in the 
graph around the -0.2V was what was looked for, as an indication of successful detection of the 
lactic acid substrate. The lactate oxidase, especially when tested in the 5mM solution of lactic 
acid, compared to the coated electrode in deionized water, showed this characteristic peak. 
However, the lactate dehydrogenase coating did not show a significant peak, though it did level 
off temporarily at. This may be due to the fact the dehydrogenase reaction does not produce 
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peroxide. The peroxide is mostly responsible for the spike at -0.2V, because this is the voltage 
where is it is the most reactive. 
The amperometry tests were conducted for 120 seconds at a constant voltage of -0.2 V. 
There were mixed results for both the oxidase and dehydrogenase coatings. However, despite 
some outlier data, the general trend was that the absolute value of the current detected increased 
as the concentrations of lactic acid increased. This was expected, as the more lactic acid present, 
the greater the level of the reaction taking place, leading to current increasing. This is also 
consistent with the previous MQP‘s finding. However, due to ouliers being present in most 
rounds of testing, it is important to note that for in vitro and in vivo clinical use that the 
equipment is highly sensitive to small changes in current and is correctly calibrated. According 
to the testing, the current readouts for even 5mM of lactic acid are only in the µAmps range. 
Therefore, even small changes to testing procedures can cause less accurate data to accumulate. 
A limitation that was detected during the cyclic voltammetry and amperometry testing 
was the relationship between chitosan and acidic environments. As stated in Chapter 2, chitosan 
shows a greater to propensity to dissolve in acidic solutions. However, the time was relatively 
short that the chitosan film spent immersed in each acidic solution, on the order of several hours. 
It appears that the combination of the immersion within an acidic solution and the rinsing in 
between each test caused the coating to slowly come off. However, this would be classified as a 
testing limitation as opposed to the chitosan being a failure for the coating. If the coating was 
used to detect in vitro with blood, or was implanted in vivo, the acidic pH issues would no longer 
be present due to blood having a pH of 7.4.  
The real time testing was inconclusive. Each time the lactic acid was added to the testing 
solution, there should have been a sharp spike in the current, followed by the amperometry 
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current readout leveling off at a larger current value. For the lactate oxidase the current spiked 
after the administration of the lactic acid, but did not remain higher than the deionized water 
baseline. The current also did not level off as expected. The lactate dehydrogenase did not show 
any of the characteristic spikes. However, after the second quantity of lactic acid was 
administered, the current rapidly increased and remained at that level for the duration of the test. 
It is likely that when the lactic acid was applied, it did not instantaneously diffuse to equilibrium, 
accounting for some of the unusual current outputs detected from both coatings. In addition, 
there was the possibility during the application of the lactic acid the electrode setup was slightly 
jarred, imperceptible to the applicator. Any change orientation of the electrodes towards one 
another during the cyclic voltammetry and amperometry tests can cause a change in the current 
output for that specific test. 
Duration 
One of the major limiting factors to this project was the length of time allotted for its 
completion. The full details of this project were received in early September 2015. The full 
report was due for submission on April 28, 2015. Therefore, all of the background research, 
planning, acquisition of necessary materials, testing, and writing were required to be completed 
in less than eight months. The time span especially affected the project, in that if would not have 
been possible for a lactate oxidase kit to be delivered by the time it would have been necessary. 
This necessitated the ordering of the similar enzyme lactate dehydrogenase. This was an 
unexpected turn that required more research that had not been planned on. Fortunately, there was 
lactate oxidase enzyme left over from the 2013-2014 biosensor MQP that was stored properly at 
-20˚C. By testing the lactate oxidase in the chitosan coating, it was determined that the enzyme 
was still active. 
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Budget 
The budget was another limiting factor of this project. The lactate dehydrogenase kit was 
purchased for $500, surpassing the initial budget of $450. It was very fortunate for this project 
that Professor Jain was willing to purchase the lactate dehydrogenase kit for her lab and allowed 
us to use what we needed. Professor Jain‘s lab also already had chitosan, lactate acid, and lactate 
oxidase. Additionally, Professor Zhou‘s lab provided two glassy carbon electrodes, the Autolab 
machine, alumina powder, and the materials for the nanotubes and nanoparticles. 
As can be seen in the budget, most of these materials are fairly expensive, at least in the 
context of startup cost. For example, only minimal amounts of the already depleted chitosan 
powder were used to make the chitosan solution. In fact, after the correct molar ratios were 
determined, the 25mL of chitosan solution made lasted the entire for the entire remainder of the 
project. Therefore, if this coating was made for a commercial purpose, it would likely be 
economically viable for customers to purchase. This is because for this project the only small 
amounts of the bulk required for purchase were utilized, something that would not be an issue 
with mass production. 
Application 
The purpose of utilizing chitosan as a biosensor coating was to compare it to the 
polypyrrole coating developed by the 2013-2014 MQP. The main improvement was the ease of 
application for the chitosan coating compared with the polypyrrole. In addition to the process of 
polishing the glassy carbon electrode, the polypyrrole coating required a half hour of the 
electrode immersed in deionized water containing polypyrrole flakes, subject to a constant 
voltage with the Autolab machine and GPES software. The full details of this procedure can be 
found in the 2013-2014 MQP report. The chitosan application by drop analysis is much simpler, 
by just dropping the chitosan/enzyme mixture on the surface of the electrode and allowed to dry. 
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This requires less of overview time, meaning that the person applying the coating has to be 
physically present less time. 
However, a drawback to the chitosan drop method is the volume of the coating used 
varies with the surface area size of the electrode. Therefore when first depositing the coating on a 
new electrode is a process of trial and error. However, to avoid using up to much of the enzyme, 
the volume required for deposition can be first tested using deionized water and the chitosan 
solution without any enzyme. In addition, the dehydrogenase coating appeared to spread evenly 
across the electrode surface after deposition. Contrastingly, the oxidase coating was resistant to 
spreading, producing a smaller area of coating coverage, despite attempts at dropping the 
mixture over the entire surface. As both coatings were deposited on the carbon electrode in 10µL 
quantities, it is a reasonable assumption that the oxidase coating was thicker than the 
dehydrogenase coating. 
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Chapter 7:  Final Design and Validation 
Standards 
Due to the nature of the biosensor produced as a result of this project, there are several 
material properties that it must possess to be considered safe for widespread patient use. These 
properties are especially important for any future in vivo implantations. The major standard that 
this product must meet to be manufactured and marketed in industry is biocompatibility, outlined 
in ISO 10993. Some of the product properties that must be tested for under ISO 10993 are 
cytotoxicity, hemocompatibility, and carcinogenicity (Food and Drug Administration, 1995). 
Actual testing of the biosensor with respect to these properties was not completed as part of this 
project due to the focus on providing an in vitro proof of concept. However, the materials 
selected (chitosan, titanium dioxide, etc.) were specifically picked due to being detailed multiple 
literary sources as having good biocompatibility, low immune response, and no have no evidence 
of carcinogenicity. 
An example of an in vitro test to determine cytotoxicity and overall biocompatibility is 
direct contact test. In this test, biosensor is placed in separate cells cultures consisting of cell 
types that would be present at the site of implantation, such as blood, bone, muscle, and nerve 
cells. After several days, the experimental cells, containing the biosensor, would be compared to 
control cell culture samples of each type to determine if any abnormal behavior is occurring, 
including cell death. If the in vitro testing were successful, then the next step would be to 
conduct in vivo testing to determine if there are differences upon implantation into a mammalian 
body. Animal trials should be done starting with lower orders of mammals, such as rats. Upon 
successful completion in small mammal testing, the device should then be implanted within 
mammal even closer to human physiology, such and pigs and primates. The final set of testing 
prior to FDA approval would be human clinical trials. 
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Economics 
It is very expensive to monitor cancer growth and development, especially in the brain, 
with current technology. The current gold standard, an MRI scan, is estimated to cost $18,167 
over a 25-year span for the average patient (Moore, 2009). This high cost is especially significant 
when taking into account that most patients only get an MRI scan every six months, as well as 
any other hospital expenses incurred. By using this type of sensor either in vitro or in vivo, there 
would be an improvement over the current gold standard of MRI scans. This is because the in 
vitro testing could be performed at a doctor‘s office, which is less expensive than hospital visits. 
Eventually, this biosensor technology might be capable of being used by the patient in a similar 
method to a glucose meter that diabetics use. Additionally, a biosensor implanted in in vivo 
would provide real time data signals, and only require doctor appointments at the end of the 
biosensors lifespan or if abnormal metabolite levels are detected. 
Environmental Impact 
The enzymatic biosensor will contain biological material, especially when utilized for 
blood testing. Therefore, after its use the sensor will need to be placed in a biological or medical 
waste container for proper disposal. Assuming that the medical waste is handled according to the 
law, the TiO2 nanotubes and enzymatic coating should not pose any threat or negative effect to 
the environment. Even if the biosensor was incorrectly disposed of, the chitosan and enzyme will 
eventually degrade as they are of biological origin. The TiO2 material is also known to be 
biologically inert in virtually all circumstance, meaning that even incorrectly disposed biosensors 
should not have a significant impact on life in the natural environment. 
Societal Influence 
We could market our product in many ways. Two main methods of marketing the 
biosensor would be to sell to healthcare professionals and institutions or directly to 
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pharmaceutical to be purchased by patients. If the product cost was reduced to make the 
biosensor affordable for people with average incomes, it could be possible for many brain tumor 
patients to monitor their own lactate and glutamate levels. Lactate is a very important metabolite 
in the bloodstream of ordinary people with brain tumors, athletes and newborn babies. The 
impact on the ordinary people can be huge with the developed biosensor. People will be able to 
monitor their lactate levels with one simple test from home.  
Political Ramifications 
The high upfront cost of imaging machines such as MRI and CT, as well as the cost to 
use and maintain, make these machines difficult to rely upon for monitoring brain tumors in 
impoverished countries. If this biosensor technology could be mass-produced, the price of the 
sensor has the potential to decrease to feasible levels for these countries to use. However, this 
still leaves the issue of being able to afford medical treatment for the brain cancer. In spite of 
this, technology such as the biosensor developed during this project is the first step towards 
removing cost as limiting factor in detecting cancer. 
Ethical Concerns 
When real time monitoring is used with a biosensor there needs to be device receiving the 
information that the sensor is picking up. This may be a computer that a doctor or medical 
professional can access for diagnostic purposes. If the chain of information in this kind of remote 
monitoring system is compromised then a patient‘s right to confidentiality and privacy could be 
violated. 
Health and Safety Issues 
 In the case of developing this biosensor to have an in vivo application, the safety of the 
patient needs to be the greatest priority. Because the biosensor is detecting levels of lactate in the 
patient‘s blood, safety issues such as risk of infection should be considered. While there are other 
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implantable devices on the market such as an insulin pump for someone with diabetes, the risk of 
infection should be outweighed by the benefits of accurate and reliable real time early tumor 
detection to detect tumors at a smaller size and increase the patient‘s chance for a longer life. 
Manufacturability 
The ease of reproducing the biosensor manufactured during the course of this project is 
likely to be high. The biosensor is not very complicated to construct. This claim is based on the 
fact that three undergraduate students were capable of researching, designing, and constructing 
this biosensor within a time span of 28 weeks of active work. Therefore, laboratories and 
companies with far more experience should be able reproduce the biosensor that we created. The 
biosensor was difficult to develop, build, and test on the budget received for this project. 
However, this cost is relatively affordable within the allocated budgets for most companies.  
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Chapter 8: Conclusions and Recommendations 
Further Testing 
Cell Media and Blood Testing 
The eventual purpose for the technology developed during this project is aimed at either 
an in vitro sensor for lactate, similar to a glucose meter used by diabetics, or an implanted sensor 
in vivo for real time monitoring. Therefore, testing the ability of the biosensor to detect lactic 
acid in media containing glioblastoma cells and later blood from cancer patients would be highly 
beneficial. The main advantage that testing with these substances is that they contain other 
substances besides the lactic acid and deionized water solution used for the tests detailed in this 
report. Therefore, this would test the sensor‘s ability to detect the lactic acid, even with the 
presence of other interfering substances. An additional benefit is that the cell media and blood 
have relatively neutral pHs. This would remove the weakness of the chitosan in the coating 
starting to dissolve, which would be bad in the case of an eventual implantation. 
Glutamate Biosensor 
With an increased budget, a glutamate biosensor could be engineered in addition to the 
lactate biosensor. A glutamate biosensor would provide the ability to test glutamate levels, which 
are also beneficial in early brain tumor detection. Glutamate dehydrogenase and glutamate 
oxidase enzymes both exist, as detailed in the background section. Therefore, in theory, by 
following the same procedure as for the lactate biosensor, either glutamate enzyme can be 
immobilized to produce the same redox reaction. Each biosensor created requires funds for 
materials and testing, thus an increased budget would allow for this capability. 
Carbon v. Platinum 
The current biosensor model utilized a glassy carbon material for the electrode, however 
with increased time a platinum based biosensor could be engineered as the electrode material. 
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Theoretically, a platinum electrode should produce more accurate and reproducible results due to 
increased enzymatic stability. Platinum electrodes require more time to engineer and prepare, 
however if additional time was granted, this would be a worthwhile endeavor.  
Titanium Dioxide Nanotubes 
The initial goal of this project was to test the chitosan coating on titanium dioxide 
nanotubes being developed concurrently by a chemical engineering MQP group. However, time 
constraints prevent the successful testing of both together. The nanotubes are infused with 
metallic nanoparticles, such as platinum or nickel that react with hydrogen peroxide, and 
generate a current. For this purpose, the lactate oxidase enzyme would be the ideal pick. This is 
opposed to lactate dehydrogenase, which does not cause peroxide to form as a byproduct of 
catalyzing a reaction with lactate. 
Coatings 
Fresh Coatings 
An increased budget would allow us to but a fresh coating on the biosensor for each test that is 
run. Both lactate coatings utilized on the electrode have a limited number of uses with the same 
coating until results are no longer accurate or detectable. An increased budget would allow for 
coating materials, and thus those coating to be put on the electrode for each test. This would 
almost guarantee accurate test results each time, without the risk of skewed test results. 
Alternatives 
There are other types of biomaterials that have been successfully used in enzymatic coatings for 
biosensors. One of these materials is polypyrrole. As detailed in the alternative designs section of 
Chapter 4, polypyrrole can be used alone, or in combination with chitosan to form a biosensor 
coating. It is recommended that a future team look into a chitosan and polypyrrole mixture for an 
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enzyme immobilization coating, as polypyrrole coating has been tested by a previous MQP team 
with promising implications. 
Future Medical and Commercial Utilization 
The technology present in this biosensor can be utilized in other areas of society besides 
cancer detection. 
Athlete Performance Testing 
As lactate is the waste product of consumed glucose, it can be an important metabolite to 
monitor for athlete performance testing. Lactate levels will indicate how hard muscles are 
working (ie. how much glucose they are using up). In the most strenuous and extreme of 
activities, 25uM of lactate can be detected in the bloodstream. Thus, exertion and maximum 
performance testing may be conducted using a lactate biosensor.  
Fetal Health Monitoring 
Immediately before birth, lactate levels from the scalp blood of the fetus can be drawn for 
health purposes. The lactate levels in the fetal blood will serve as an indication of the heart health 
of the fetus, and tell doctors whether or not the baby will likely survive the birthing process 
(since oxygen levels will decrease upon birth). Elevated lactate levels are an indication that the 
fetus is not receiving enough oxygen and their heart health is not strong enough to survive the 
birthing process without assistance.  
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Appendices 
Appendix A: Design Protocols 
Applying Polypyrrole to Electrode 
Before preparing the polypyrrole for application to the electrode, the electrode must first 
be prepared. This includes polishing the electrode, then ultrasonicating it in a solution such as 
methanol for 1-2 minutes. After the electrode is polished and has completely dried, the solutions 
may be applied. Before applying the polypyrrole, many research teams suggest creating a 
‗polypyrrole prelayer‘. This is meant to help the enzymes adhere in a smooth layer and allow for 
the electrode to obtain an accurate reading. In order to apply this prelayer, the electrode is soaked 
in a 0.1M solution of LiCl04 and 0.05M pyrrole solution. This solution should be applied just 
long enough to coat the surface of the electrode and allowed to dry at room temperature. The pH 
of the polypyrrole layer should be around 6.2 (Razola et al., 2002). After this prelayer has been 
added to the electrode, the actual polypyrrole layer can be added. The polypyrrole is prepared by 
adding 6ul of polypyrrole to 1mL of phosphate buffered saline (PBS) with a pH of 7.4. Once this 
solution is thoroughly mixed, immerse the electrode in the solution and allow to completely dry. 
Once the electrode has dried, rinse the electrode with deionized water and let dry (Ammam, 
2009).  
Applying Chitosan to Electrode 
The process of applying chitosan to the electrode of the lactate biosensor involves 
preparing the material into a usable form in order to achieve its full functional potential. The 
simplest and most efficient way to prepare the chitosan to make a film for the biosensor is to 
begin with chitosan chips or flakes, purchased from a chemical company such as Sigma-Aldrich 
or Fisher Scientific (Zhang et al., 2006). By examining several protocols from various research 
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teams who have applied chitosan to their biosensor electrode with other materials, we have 
formulated the following protocol:  
Beginning with chitosan flakes purchased from a chemical manufacturer, we will prepare 
a 0.10 wt.% chitosan solution. This seems to be the most effective concentration of chitosan for 
creating a film, especially if it is to be layered with other materials. To prepare this solution, a 
measured value of (depending upon the desired chitosan solution necessary) will be massed and 
dissolved in heated 0.1M hydrochloric acid (HCl). The HCl should be heated to around 80°C in 
order for the chitosan to properly dissolve into solution. Adjust this solution to a pH level of 4.5 
using either HCl to lower the pH or sodium hydroxide to raise the pH (if at all necessary). Use 
either a pH test strip or an automated pH bench top meter to check the solution for necessary 
adjustments. Filter the solution through a 0.45-micron or lower filter in order to ensure sterility 
and the absence of foreign particulates. This solution can be stored in a 4°C refrigerator until it is 
ready for use. Once this chitosan solution has been prepared, it can be added to the electrode, 
typically in a 15-20ul quantity, however, for our electrode we only applied a 10ul volume in 
order to reduce the film thickness. This would allow the substrate to access the enzyme 
throughout the film during testing. At this point, the solution should become somewhat 
gelatinous and another solution layer may be added to the electrode (Zhang et al., 2006). The 
figure below from Chapter 4 (Figure 18) illustrates how the chitosan will be applied atop the 
TiO2 electrode. 
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Crosslinking Oxidase with PEGDE 
In the protocol found for crosslinking with PEGDE, the authors used glutamate oxidase, 
where our biosensor detects lactate. The following protocol would be modified to account for 
this. The glutamate oxidase was immobilized on the surface by crosslinking with PEGDE. Once 
the polypyrrole or chitosan was successfully polymerized on the electrode, the oxidase enzyme 
was immobilized in a solution with 57mg/ml of glutamate oxidase, 81mg/ml BSA, 10mg/ml 
PEGDE and 1% glycerol in PBS (0.01M). This solution was applied to the electrode and the 
electrode was heated to 55 degrees Celsius for 2 hours to complete the crosslinking of the 
enzyme (Vasylieva, 2011). 
Appendix B: Lactate Assay Protocol for Chitosan Film Testing 
Materials/Solutions: 
 Make a 2% BSA solution in PBS  
Part 1: Block Chitosan Wells 
1. Add 50-100ul of 2% BSA in PBS to each chitosan well 
2. Let it stand for 1-2 minutes 
3. Pipette liquid out carefully 
4. Repeat this 2X (3 times total) 
5. Add 50-100ul PBS to each chitosan well 
6. Let it stand for 1-2 minutes 
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7. Pipette liquid out carefully 
8. Repeat (2 times total) 
Part 2: Binding in Chitosan 
1. Mix 10ul of standard with 990ul of buffer  
2. Add lactate standard of 6nmol/well standard to each chitosan well. Let it stand for 1 hour 
(standard 4 is 18ul standard, 126ul buffer) 
3. While lactate is incubating/binding, make standard curve: 
a. Follow the chart and make 150ul of each standard in a tube, then take 50ul for 
each well and make the standard in duplicate 
b. Make standards 
i. Standard 1: 120ul buffer 
ii. Standard 2: 6ul standard, 144ul buffer 
iii. Standard 3: 12ul standard, 138ul buffer 
iv. Standard 4: 18ul standard, 132ul buffer 
v. Standard 5: 24ul standard, 126ul buffer 
vi. Standard 6: 30ul standard, 120ul buffer 
c. Take 50ul per standard well, standards in duplicate. 
4. After 1 hour: Add 50-100ul of PBS into each chitosan well 
5. Let it stand for 1-2 minutes. 
6. Repeat (2 times total). 
Part 3: Reaction Mix and Incubation 
1. Make enough reaction mix for every standard well and sample well. The kit suggests the 
equation: Xul component * (number of reactions + 1) where Xul components are: 
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a. 46ul lactate assay buffer, 2ul lactate substrate mix, and 2ul lactate enzyme mix 
(50ul reaction mix per well). 
2. Mix each well by pipetting up and down gently. 
3. Background Reaction Mix 
a. 48ul lactate assay buffer and 2ul lactate substrate mix (50ul/well) using the same 
formula above. 
4. Incubate at room temperature for 30 minutes. 
Part 4: Plate Reader 
1. Read at 450nm. 
Appendix C: Material Cost 
The materials used in our film design include chitosan, L-lactic acid (substrate), a L-
lactate assay kit (contained lactate dehydrogenase enzyme used in the film), as well as lactate 
oxidase enzyme from a lactate assay kit. The Chemical Engineering group used materials not 
included in our MQP budget to synthesize the titanium dioxide nanotubes with deposited 
nanoparticles. 
Material Cost Analysis: 
 
Material Description Price Availability 
Chitosan Sigma Aldrich (10G), 
in powder/flake form 
$33.10 In lab 
L-Lactic Acid 
 
85-90% pure             
L-lactate, approximate 
molarity of 9.4M 
Unknown In lab 
L-Lactate Assay Kit 
(Colorimetric) 
Abcam, enzyme used 
is lactate 
dehydrogenase 
$549.00 Ordered from Abcam 
website 
Lactate Assay Kit Sigma Aldrich, 
enzyme used is lactate 
oxidase 
$458.00 In lab from previous 
MQP 
 
